Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (AvastinĀ®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial
Titel:
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (AvastinĀ®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial